Research - We're nearly two months into the equity markets' deepest correction since August 2011. The S&P 500 bounced handily from its August lows at the end of September, and this week is close to retesting its latest level of resistance.
Premium: Read NowResearch - It's not easy. But the good news is - you don't have to.
Read NowResearch - After a brutal session for the biotech sector (NBI dropped 6% for the day) ESPR fell another $3 in after hours on one particular line in a Monday afternoon press release.
Premium: Read NowResearch - What a crazy end of summer. Thankfully, today’s the first day of Fall. We’ve got a bunch of updates – insights and administrative – for … Continue Reading
Premium: Read NowResearch - Over the weekend, the scientific and investing communities had a first look at 1-year follow-up results for AMT-110, uniQure’s (QURE) gene therapy candidate for the treatment of Sanfilippo B.
Read NowResearch - UniQure’s (QURE) presentation of 1-year follow-up data from patients with Sanfilippo B (MPS IIIB) and treated with the gene therapy AMT-110 is only a week … Continue Reading
Read NowResearch - Last week was yet another exhausting, anemic few sessions in the markets. One day we're up, and the next we're down - with gaps nonetheless - but a trend is non-existent.
Premium: Read Now
